Haemonetics Corporation surged 16.3% on Tuesday after announcing a non-exclusive supply agreement with CSL Plasma Inc., a U.S. plasma collection subsidiary of CSL Limited.
Under the terms of the deal signed on August 14, 2026, CSL Plasma may deploy Haemonetics' NexSys PCS devices equipped with Persona PLUS technology across its U.S. plasma collection centers. The agreement also includes the purchase of related disposables, though no minimum purchase commitments have been specified.
The scope and timing of the transition remain undetermined, as CSL Plasma evaluates the integration of the new equipment. Haemonetics stated it will not revise its fiscal 2027 financial guidance until implementation details are finalized. The company plans to provide an update on the expected impact during its second fiscal quarter earnings call scheduled for November 2026.
Haemonetics, which trades on the New York Stock Exchange under the ticker HAE, did not disclose the financial terms of the agreement beyond the absence of minimum purchase obligations.
